Pharmaceutical

Theratechnologies (TSX:TH) is pleased to announce that Trogarzo (ibalizumab-uiyk) injection is now included in the most recent version of the treatment guidelines issued by the United States Department of Health and Human Services. As quoted in the press release: The DHHS guidelines state that “Patients with ongoing detectable viremia who lack sufficient treatment options to construct …

Theratechnologies (TSX:TH) is pleased to announce that Trogarzo (ibalizumab-uiyk) injection is now included in the most recent version of the treatment guidelines issued by the United States Department of Health and Human Services.

As quoted in the press release:

The DHHS guidelines state that “Patients with ongoing detectable viremia who lack sufficient treatment options to construct a fully suppressive regimen may be candidates for the recently approved CD4 post-attachment inhibitor ibalizumab.”

“We are very pleased with these guidelines. They recognize the unique mode of action of Trogarzo® and they confirm its usefulness in patients who cannot decrease their viral load below detection despite being on other antiretrovirals. The DHHS guidelines should give even more traction with physicians and payers in the United States,” said Luc Tanguay, President and CEO, Theratechnologies Inc.

“After the publication of treatment guidelines by the International Antiviral Society and the publication of the phase III clinical trial results in the New England Journal of Medicine, this is yet another major milestone for Trogarzo® which should generate even more interest in the product and support sales,” added Mr. Tanguay.

Click here to read the full press release.

MARKETS

Markets
TSX19991.88+105.94
TSXV673.02+3.30
DOW33336.67+27.16
S&P 5004207.27-2.97
NASD12779.91-74.89
ASX7071.00+78.30

COMMODITIES

Commodities
Gold1792.88+3.89
Silver20.43+0.16
Copper3.70-0.01
Palladium2262.49-13.51
Platinum961.23+6.22
Oil94.20-0.14
Heating Oil3.480.00
Natural Gas8.70-0.18

DOWNLOAD FREE REPORTS

×